Predictive modelling of a novel anti-adhesion therapy to combat bacterial colonisation of burn wounds by Roberts, Paul A et al.
RESEARCH ARTICLE
Predictive modelling of a novel anti-adhesion
therapy to combat bacterial colonisation of
burn wounds
Paul A. Roberts1,2*, Ryan M. Huebinger3, Emma Keen2, Anne-Marie Krachler4,
Sara Jabbari1,2
1 School of Mathematics, University of Birmingham, Edgbaston, Birmingham, United Kingdom, 2 Institute of
Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham, United
Kingdom, 3 Department of Surgery, University of Texas Southwestern Medical Center, Dallas, Texas, United
States of America, 4 Department of Microbiology and Molecular Genetics, University of Texas McGovern
Medical School at Houston, Houston, Texas, United States of America
* p.a.roberts@univ.oxon.org
Abstract
As the development of new classes of antibiotics slows, bacterial resistance to existing
antibiotics is becoming an increasing problem. A potential solution is to develop treatment
strategies with an alternative mode of action. We consider one such strategy: anti-adhe-
sion therapy. Whereas antibiotics act directly upon bacteria, either killing them or inhibiting
their growth, anti-adhesion therapy impedes the binding of bacteria to host cells. This pre-
vents bacteria from deploying their arsenal of virulence mechanisms, while simultaneously
rendering them more susceptible to natural and artificial clearance. In this paper, we con-
sider a particular form of anti-adhesion therapy, involving biomimetic multivalent adhesion
molecule 7 coupled polystyrene microbeads, which competitively inhibit the binding of bac-
teria to host cells. We develop a mathematical model, formulated as a system of ordinary
differential equations, to describe inhibitor treatment of a Pseudomonas aeruginosa burn
wound infection in the rat. Benchmarking our model against in vivo data from an ongoing
experimental programme, we use the model to explain bacteria population dynamics and
to predict the efficacy of a range of treatment strategies, with the aim of improving treat-
ment outcome. The model consists of two physical compartments: the host cells and the
exudate. It is found that, when effective in reducing the bacterial burden, inhibitor treat-
ment operates both by preventing bacteria from binding to the host cells and by reducing
the flux of daughter cells from the host cells into the exudate. Our model predicts that inhib-
itor treatment cannot eliminate the bacterial burden when used in isolation; however, when
combined with regular or continuous debridement of the exudate, elimination is theoreti-
cally possible. Lastly, we present ways to improve therapeutic efficacy, as predicted by
our mathematical model.
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1006071 May 3, 2018 1 / 28
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Roberts PA, Huebinger RM, Keen E,
Krachler A-M, Jabbari S (2018) Predictive
modelling of a novel anti-adhesion therapy to
combat bacterial colonisation of burn wounds.
PLoS Comput Biol 14(5): e1006071. https://doi.
org/10.1371/journal.pcbi.1006071
Editor: Philip K Maini, University of Oxford,
UNITED KINGDOM
Received: August 9, 2017
Accepted: March 5, 2018
Published: May 3, 2018
Copyright: © 2018 Roberts et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: PAR, EK, AMK and SJ gratefully
acknowledge support from the Biotechnology and
Biological Sciences Research Council (grant code:
BB/M021386/1, http://www.bbsrc.ac.uk/). PAR
and SJ would also like to thank the Wellcome
Trust (grant code: 1516ISSFFEL9, www.wellcome.
ac.uk/) for funding a parameterisation workshop at
the University of Birmingham (UK). RMH
Author summary
Humankind is engaged in an arms race; one we are in danger of losing. Since the develop-
ment and application of the first antibiotics, resistant strains of bacteria have steadily
emerged. As the rate of discovery of new antibiotics slows, the threat increases. At present,
700,000 individuals globally die each year due to antimicrobial resistance and this number
is predicted to rise to 10 million per year by 2050 unless fresh action is taken. It is impor-
tant, therefore, that we explore alternative treatment strategies to replace or complement
traditional antimicrobials. Here we use mathematical models to explain and predict the
effects of a novel anti-adhesion therapy applied to infected burn wounds. This theoreti-
cally resistance-proof therapy operates by impeding bacteria from binding to host cells by
blocking the host cell binding sites. This prevents bacteria from accessing nutrients and
renders them susceptible to artificial clearance. Fitting our model to experimental data,
we identify a number of valid parameter sets, and predict the conditions under which
treatment will be effective for each set. These predictions are experimentally testable, and
could be used to guide the development and application of anti-adhesion treatments in a
clinical setting.
Introduction
As we begin to lose the arms race against microbial infections, it is important that we develop
new treatment strategies as a complement or alternative to antibiotics. In this paper, we use
mathematical modelling to explain and predict the effects of a novel anti-adhesion therapy in
the treatment of infected burn wounds, with the aim of improving treatment outcome.
Each year, millions of lives are saved through the use of antibiotics to combat bacterial
infections. However, sustained use of any given antibiotic leads to the clinical emergence of
drug-resistant strains. Since the discovery of penicillin, many new classes of antibiotics have
been identified, allowing clinicians to switch between antibiotics if resistance emerges either
within an individual patient or within a patient population [1]. Over time, strains have
emerged which exhibit resistance to multiple classes of antibiotics (multi-drug resistance) and
reports of bacterial infections which are resistant to all known antibiotics (pan-resistant) are
becoming increasingly common. At present, a reported 700,000 individuals worldwide die
each year due to antimicrobial resistance and this figure is predicted to rise to 10 million per
year by 2050 unless steps are taken to combat this threat [2]. While resistant strains continue
to evolve, our ability to develop new classes of antibiotics is diminishing, the rate of antibiotic
discovery having slowed significantly since its ‘Golden Era’ in the 1940s–1960s [1, 3]. It is
therefore vital that we develop alternative treatment strategies to replace or complement anti-
biotics [4, 5].
One potential way forward is through the use of anti-virulence treatments. Whereas antibi-
otics either kill bacteria (bactericidal) or inhibit their growth (bacteriostatic), anti-virulence
treatments interfere with a pathogen’s ability to cause damage and disease in the host [6]. As
such, they are likely to exert a smaller selective pressure upon a bacterial community, reducing
the chances that resistance will develop (though opinions vary over the extent to which they
may be resistance-proof, see [7, 8]). Anti-virulence treatments take a number of forms includ-
ing those which target or inhibit toxin activity, adhesion, toxin secretion, virulence gene
expression and inter-bacterial signalling [9–11].
In this paper, we consider a form of anti-adhesion treatment consisting of polystyrene
microbeads coupled to a protein known as multivalent adhesion molecule (MAM) 7 (see also
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[12] and other papers from their group for alternative anti-adhesion treatments that operate
by blocking pilus assembly or function). MAM7 is anchored in the outer membrane of many
Gram-negative bacteria, where it is responsible for initiating attachment of bacteria to host
cells [13, 14]. When applied to an infection site, MAM7-coated beads (henceforth, inhibitors)
act as a bacteriomimetic, competitively inhibiting the infectious agent from binding to host
cells. This prevents bacteria from deploying those virulence mechanisms for which cell-to-cell
contact is required and renders them more susceptible to natural or artificial physical clear-
ance. Given that inhibitors must bind to host cells before bacteria in order to block them from
binding, it is unclear whether their application may ever be expanded from prevention (pro-
phylaxis) to the treatment of established infections (therapy).
Bacterial infection is a major cause of mortality in patients with burn wounds, where it is
responsible for up to 75% of deaths in cases where severe burns are sustained to more than
40% of the body surface area [15]. Burn wounds are commonly infected by Pseudomonas aeru-
ginosa [15–18], an opportunistic Gram-negative bacterium; the infection often being hospital-
acquired (nosocomial) [15, 19].
Current treatment of such infections involves use of topical and systemic antibiotics, and
regular debridement (mechanical wound cleaning). Debridement is either achieved through
regular wound cleansing with a cloth, or through application of negative pressure devices (neg-
ative pressure wound therapy, NPWT) in which fluid is drawn out of the wound, either contin-
uously or intermittently, using a pump, attached to a foam dressing covering the wound [20].
Some studies have shown NPWT to be effective in reducing the bacterial burden [21]; how-
ever, this result is not consistent across all studies [20, 22].
In earlier work we have shown, using an experimental model for P. aeruginosa burn wound
infections in the rat, that treatment with inhibitors can significantly reduce the bacterial bur-
den in the wound without impeding wound closure [23] (see Experimental set-up for more
details). In vitro studies have also demonstrated the efficacy of inhibitor treatment in reducing
cytotoxicity [9, 24] and have shown that inhibitors do not interfere with host cell functions
critical to wound healing [25].
A number of mathematical modelling studies have considered the use of anti-virulence
treatments to combat bacterial infections. The majority of these studies focus upon anti-quo-
rum sensing treatments (see, for example, [26–33]). An exception to this rule; the model in
[34] is of particular relevance to the present work. This ordinary differential equation (ODE)
model considers a general anti-virulence treatment, which operates by enhancing innate
immunity in bacterial clearance. The model predicts that, when used in isolation, anti-viru-
lence treatment is unlikely to eliminate a bacterial infection. However, the model predicts that,
when combined with antibiotics, anti-virulence treatments could eliminate bacteria, provided
antibiotic and anti-virulence treatments are applied in staggered doses. Other modelling work
has considered the bacterial invasion of burn wounds and the resultant tissue damage [30, 35–
37], the influence of bacterial infection upon the healing of burn wounds [38] and the effects
of ambient gas plasma treatment in this context [39]. Each of these models is formulated as a
system of partial differential equations in one or two spatial dimensions. Models have also
been developed to describe microbial adhesion to surfaces, for example, [40] developed an
ODE model for the competitive colonisation of the gut wall by host and invader strains of
Escherichia coli. Lastly, [41] have developed an individual-based model to describe the coloni-
sation of a generic surface by phenotypically heterogeneous bacteria, in which bacteria may
migrate between the surface and a liquid medium.
In this paper, we construct a mathematical model, formulated as a system of ODEs, to
describe the population dynamics and treatment of a bacterial infection within a burn wound.
Basing our mathematical model upon Huebinger et al.’s [23] experiments, we use it to explain
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the empirical results and to predict the effects of various treatment regimes, involving inhibitor
dosing and debridement, with the aim of improving efficacy. A particular strength of this
study is that we consider multiple parameter sets, twelve in total, each of which provides a
good fit to the experimental data. Classifying these sets into four qualitatively different cases,
we consider the long-term effects of each treatment strategy, predicting the conditions under
which treatment will eliminate the bacterial burden across all four cases.
Materials and methods
Experimental set-up
In this section we provide a simple description of the experimental set-up which forms the
basis for our mathematical model. The experimental work was published previously in [23],
wherein a more detailed description can be found.
We consider a burn wound infection model in the Sprague-Dawley rat (see Fig 1). Rats
were anaesthetised and the portion of each rat which was to be burned was shaved. Rats were
then immersed in 100˚C water for 12s resulting in full-thickness cutaneous burns to 40% of
the body surface area, in a region spanning the back and upper sides of the body. We label the
time at which the burn is administered as day −2. Rats were then resuscitated and given the
appropriate pain control for the remainder of the experiment. On day 0, two days after the
Fig 1. Diagram summarising the experimental set-up. (a) Burns were administered to the backs of the rats on day
−2. On day 0 a region of eschar (dead) tissue was excised and bioluminescent P. aeruginosa were applied to the
excision, followed by suspensions containing either inhibitor or control beads. Rats were imaged every 24 hours on
days 1-6 post infection. (b) Exemplar images of burn wounds to which control beads (top) and inhibitor (bottom) were
applied. In each image, the dark-grey area is the excision, the light-grey region is the non-excised burn wound, the
white region is healthy, fur-covered tissue, and the coloured regions (colour online) denote the presence of bacteria,
red corresponding to high density and blue to low density. The bacterial population increases in size and spreads much
more rapidly across the burn wound in the control scenario than when inhibitor is used. See Experimental set-up for
more details. d.p.i.: days post infection. Figure reproduced, with modifications, from [23], where it was published
under a CC-BY 4.0 license.
https://doi.org/10.1371/journal.pcbi.1006071.g001
Predictive modelling of a novel anti-adhesion therapy
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1006071 May 3, 2018 4 / 28
burn was administered, a section of eschar (dead) tissue, approximately 4 × 4 cm in area, was
surgically excised. Next, 5 × 106 CFU (colony-forming units) of multidrug-resistant P. aerugi-
nosa were applied to the excised region, followed by suspensions containing either 3 × 108
inhibitor or control beads (without a MAM7 coating) in saline. Identical inhibitor and control
treatments were repeated every 24 hours for days 1–5 post infection; however, since a scab (i.e.
a layer of solidified exudate) forms over the excision by day 1, treatments administered on or
after day 1 are unlikely to enter the (liquid) exudate. Rats were euthanized after the experi-
ment, on day 6.
A bioluminescent, multidrug-resistant P. aeruginosa isolate, Xen5, was chosen, such that
the bacterial burden and their spatial distribution across the wound could be detected. An
IVIS Spectrum in vivo imaging system (Perkin Elmer) was used to record bacterial lumines-
cence on days 1–6 post infection, from which the total flux (photons sec−1) was calculated
using MetaMorph software (Molecular Devices) to integrate over the pixels. The total
number of bacteria in CFU was then calculated using the conversion factor 4 × 108 photons
sec−1$ 5 × 106 CFU, which was determined by measuring the luminescence of suspensions
which contained an experimentally determined number of bacterial colony-forming units.
13 experiments were conducted using inhibitor and 11 using control beads. Two of the con-
trol bead experiments were discounted because the exposure setting used was too high to pre-
vent the image from saturating. This may imply that the mean bacteria population size over
time calculated for the control bead scenario slightly underestimates the true mean value. The
experimental results are summarised in Fig 2.
These results raise two important questions:
1. Why does treatment with inhibitor affect the bacterial population dynamics in this way?
2. How might the treatment be adapted to improve its efficacy? For instance, this might be
achieved by altering the adhesive properties of the inhibitor, the inhibitor dosing regimen
or by combining inhibitors with other treatment strategies.
In what follows, we formulate a mathematical model of the burn wound infection experi-
ment described above to help us answer these questions.
Model formulation
The burn wound is assumed to consist of two physical compartments: the host cells, and a
fluid compartment exuded by the host cells and (hence) known as the exudate. The host cells
and the overlying exudate extend to the perimeter of the burn wound beneath the necrotic tis-
sue, while the exudate is exposed to the air at the excision (see Fig 3A). The area of the burn
wound, Ar (cm2), remains essentially fixed during the experiment; however, the exudate
height, h (cm), and volume, V (cm3), are elevated for a short period following the application
of bacteria and inhibitors to the excision at the beginning of day 0 (see Fig 1A). This excess
fluid is lost rapidly via run-off (down the sides of the rat), evaporation and absorption (into
the host cells). Since the timescale over which the height and volume are elevated (on the order
of minutes) is small compared to the timescale of the experiment (on the order of days), we
neglect this variation and assume a fixed height and volume throughout the course of the
experiment.
Both bacteria and inhibitors can exist in one of two states; either free in the exudate or
bound to the host cells (we note that inhibitors do not bind to bacteria). It is assumed that the
system is well-mixed since any given bacteria (or inhibitor) has an equal chance of interacting
with any given binding site and since all other processes (growth, clearance, phagocytosis and
unbinding) are thought not to depend upon their spatial location. This allows us to forgo an
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explicit spatial component and so to construct an ODE model for the evolution of the free bac-
teria density, BF(t) (cells cm−3), bound bacteria density, BB(t) (cells cm−2), free inhibitor con-
centration, AF(t) (inhibitors cm−3), and bound inhibitor concentration, AB(t) (inhibitors
cm−2), over time, t (hr). It is assumed that the total binding site density on the host cells, con-
sisting of both free and occupied sites, is conserved, such that the free binding site density
E(t) = Einit − ϕBacBB(t) − ϕAAB(t) (sites cm−2), where Einit (sites cm−2) is the initial density of
free binding sites, and ϕBac (sites cell−1) and ϕA (sites inhibitor−1) are the number of binding
sites occupied by a bacterium or an inhibitor respectively.
The model is summarised in Fig 3B and described by the following governing equations
dBF
dt
¼ rFBF 1  
BF
KF
 
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
logistic growth
þ ð1   ZðEÞÞHðKB   BBÞ
rB
h
BB 1  
BB
KB
 
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
daughter cells freed from host cells upon division
  aBacArBFE|ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ}
binding to host cells
þ
bBac
h
BB
|ﬄﬄ{zﬄﬄ}
unbinding
from host cells
  cBacðtÞBF|ﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄ}
natural clearance
;
ð1Þ
Fig 2. Bacterial population size for control bead and inhibitor treated rats in the experimental model. The discs
and squares show the mean bacterial population size in control bead (n = 9 animals) and inhibitor (n = 13 animals)
treated rats respectively, while the shaded regions show the standard error of the mean (that is, m s=
ffiffiffi
n
p
, where μ is
the mean and σ is the standard deviation). Treatment with the inhibitor reduces, but does not eliminate, the bacterial
burden. CFU: colony-forming units.
https://doi.org/10.1371/journal.pcbi.1006071.g002
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dBB
dt
¼ ð1þ ðZðEÞ   1ÞHðKB   BBÞÞrBBB 1  
BB
KB
 
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unbinding
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binding to
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h
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|ﬄ{zﬄ}
unbinding
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natural
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;
ð3Þ
dAB
dt
¼ aAVAFE|ﬄﬄﬄﬄ{zﬄﬄﬄﬄ}
binding to
host cells
  bAAB|ﬄ{zﬄ}
unbinding
from host cells
;
ð4Þ
where parameter values are given in Tables 1 and 2, and Table A in S2 Supporting Information.
See Parameter fitting and S1 Supporting Information for details on how the parameters were
obtained. Note that we consider multiple parameter sets, each of which provides a good fit to
the data.
Both free and bound bacteria are assumed to grow logistically with respective intrinsic
growth rates rF (hr−1) and rB (hr−1), and carrying capacities KF (cells cm−3) and KB (cells cm−2).
We interpret the carrying capacities to represent the maximum number of bacteria that can be
sustained by available nutrients and the situation in which BF(t) = KF, or BB(t) = KB, to be one
Fig 3. Diagrams showing the wound geometry and model structure. (a) Wound geometry pictured in the transverse plane. The host cells
are covered by a liquid layer known as the exudate, which is itself covered by necrotic tissue, except in the region of the excision where the
exudate is exposed to the air. (b) Diagram displaying the structure of the model given by Eqs 1–8. Bacteria and inhibitors exist in one of two
states: free in the exudate or bound to the host cells, and can transition between these states by binding to (αBac and αA) and unbinding from
(βBac and βA) the surface. Both free and bound bacteria can divide (rF and rB); daughters of free bacteria enter the exudate, whereas a
proportion, 0 η 1, of bound bacterial daughters remain bound to the surface, the remaining fraction, 1 − η, entering the exudate. Bound
bacteria may be phagocytosed by neutrophils (δB), while free bacteria and inhibitors are cleared from the wound in the first 24 hr after the
excision is made and before a scab forms over the exposed exudate (ψBac and ψA).
https://doi.org/10.1371/journal.pcbi.1006071.g003
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in which the rate of bacterial division is negligible (see [42, 43]). The burn wound exudate con-
tains glucose and other nutrients and has been shown to be capable of supporting a proliferat-
ing population of P. aeruginosa [44, 45]. We note that, in general, KB 6¼ Einit/ϕBac, such that the
number of bacteria that can be nourished on the host cells is not equal to the number that can
bind to the host cells. For all of the parameter sets considered in this paper, KB< Einit/ϕBac (see
Tables 1 and 2, and Table A in S2 Supporting Information).
It is assumed that bacteria and inhibitors bind to and unbind from the host cells in accor-
dance with the law of mass action, with respective binding rates αBac (hr
−1 sites−1) and αA (hr
−1
sites−1), and unbinding rates βBac (hr
−1) and βA (hr
−1).
Table 1. Fitted parameter values for Eqs 1–8.
Parameter Description (Units) Value
Case A Case B Case C Case D
rF Intrinsic growth rate of free bacteria (hr−1) 8.37×10−2 2.10×10−3 4.18×10−3 2.57×10−1
rB Intrinsic growth rate of bound bacteria (hr−1) 1.10×10−1 1.35×10−1 1.50×10−1 5.55
KF Carrying capacity of free bacteria (cells cm−3) 1.17×107 1.15×106 3.12×106 1.85×106
KB Carrying capacity of bound bacteria (cells cm−2) 9.96×105 1.65×106 1.48×106 1.43×106
αBac Binding rate of bacteria to host cells (hr
−1 sites−1) 1.34×10−9 3.09×10−10 2.32×10−10 3.34×10−11
βBac Unbinding rate of bacteria from host cells (hr
−1) 1.97×10−1 4.11×10−9 8.23×10−9 5.79×10−6
δB Rate of phagocytosis of bacteria by neutrophils (hr
−1) 1.06×10−3 2.31×10−4 3.97×10−4 3.02×10−5
ηmax Maximum proportion of daughters of bound cells that can enter the bound compartment
(dimensionless)
2.95×10−2 1.31×10−7 3.06×10−7 1.52×10−2
γ Concentration of binding sites at which η = ηmax/2 (sites cm
−2) 3.12×104 1.83×105 3.66×104 1.65×106
~cBac Natural clearance rate of bacteria (hr
−1) 1.42×10−1 2.13×10−6 7.68×10−6 5.01×10−1
αA Binding rate of inhibitors to host cells (hr
−1 sites−1) 1.46×10−6 1.56×10−10 2.32×10−10 5.51×10−9
βA Unbinding rate of inhibitors from host cells (hr
−1) 6.35×10−8 4.11×10−9 3.85×10−3 4.43×10−1
~cA Natural clearance rate of inhibitors (hr
−1) 4.39×10−8 2.13×10−6 3.85×10−3 1.75×10−5
αBac/βBac Bacterial association constant (sites
−1) 6.82×10−9 7.53×10−2 2.82×10−2 5.77×10−6
αA/βA Inhibitor association constant (sites
−1) 2.29×101 3.79×10−2 6.03×10−8 1.24×10−8
ðaBac=bBacÞ
ðaA=bAÞ
Ratio of association constants (dimensionless) 2.97×10−10 1.98 4.68×105 4.65×102
The last three rows give the bacteria association constant, αBac/βBac, the inhibitor association constant, αA/βA, and the ratio of bacteria to inhibitor association constants.
Values are given to an accuracy of 3 significant figures.
https://doi.org/10.1371/journal.pcbi.1006071.t001
Table 2. Measured, calculated and estimated parameter values for Eqs 1–8.
Parameter Description (Units) Value Source
ϕBac Number of binding sites occupied by a bacterium (sites cell−1) 1 Estimated
ϕA Number of binding sites occupied by an inhibitor (sites inhibitor−1) 1 Calculated
V Volume of the exudate (cm3) 4.9 (4.6) Calculated
Ar Area of the burn wound (cm2) 49 (46) Measured
h Height of the exudate (cm) 0.1 Measured
n Hill coefficient (dimensionless) 1 Estimated
BFinit Initial density of free bacteria (cells cm
−3) 1.02×106 (1.09×106) Measured
AFinit Initial concentration of free inhibitors (inhibitors cm
−3) 0 or 6.12×107(6.52×107) Measured
Einit Initial density of binding sites (sites cm−2) 2.57×106 Calculated
Measured values are those which have been measured directly, calculated values are those which have been calculated using values which were measured directly and
estimated values are those which could not be measured or calculated. The values in brackets are used only when fitting the inhibitor treatment data to the model.
https://doi.org/10.1371/journal.pcbi.1006071.t002
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Examination of histological sections through the burn wound shows that neutrophils are
present within and at the surface of the host cells, but not within the exudate [23]. Administra-
tion of a burn wound causes neutrophils to be fully activated such that no further neutrophils
are recruited in response to the bacterial infection [23, 46] (in contrast to [34]). Therefore,
the immune response can be captured by the exponential decay of bound bacteria with rate
δB (hr
−1), where δB accounts for the density of neutrophils. It is assumed that inhibitor degra-
dation, if it occurs, is sufficiently gradual that it can be neglected.
Several of the terms in Eqs 1–4 contain h, Ar or V as a factor in order to ensure dimensional
consistency. These constants could have been combined with other parameters, but we retain
them in the interests of clarity.
A proportion of the daughter cells of bound bacteria, 0 η(E(t)) 1 (dimensionless),
remain bound to the surface, while the remaining fraction, 1 − η(E(t)), enter the exudate.
Daughter cells may not bind immediately either because the long axis of the parent cell is
angled away from the host cell surface upon division or due to a lack of free binding sites on
the neighbouring host cell surface. The proportion that remains bound, η(E(t)), depends upon
the density of free binding sites, E(t), such that a larger fraction of the daughter cells remain
bound when more binding sites are available. We capture this dependence using a Hill func-
tion with constant γ (sites cm−2) and Hill coefficient n (dimensionless) as follows
ZðEÞ ¼
ZmaxEn
gn þ En
; ð5Þ
where ηmax (dimensionless) is the maximum proportion of daughter cells which may remain
bound to the surface. If the density of bound cells, BB(t), exceeds the bound carrying capacity,
KB, then the bound logistic growth term becomes a death term. In this case, the loss of bacteria
is confined to the bound compartment and does not affect the free compartment. This is
achieved through the use of a Heaviside step function, H(KB − BB(t)), in Eqs 1 and 2, where
HðxÞ≔
0 if x < 0;
1 if x  0:
(
ð6Þ
The rates of clearance of bacteria and inhibitors, ψBac(t) (hr−1) and ψA(t) (hr−1), vary with
time, such that clearance occurs at a constant rate for the first 24 hours and then stops after
this point due to the formation of a scab over the excision. Thus, clearance occurs at rates
cBacðtÞ ¼ ~cBacHð24   tÞ and cAðtÞ ¼ ~cAHð24   tÞ; ð7Þ
where ~cBac (hr
−1) and ~cA (hr
−1) are the constant rates of clearance in the first 24 hours, and H
is a Heaviside step function, as defined in Eq 6.
We choose the time t = 0 (hr) to correspond to the point at which bacteria and inhibitors
are applied to the burn wound following the excision. Bacteria and inhibitors are present only
in the free compartment initially, not having had the opportunity to bind to the host cells, such
that
BFð0Þ ¼ BFinit ; BBð0Þ ¼ 0; AFð0Þ ¼ AFinit ; ABð0Þ ¼ 0; ð8Þ
where BFinit and AFinit are constants. See Tables 1, 2 and Table A in S2 Supporting Information
for parameter values.
The parameters in Table 1 and Table A in S2 Supporting Information were fitted to the
experimental data (see Parameter fitting and S1 Supporting Information for details), while
those in Table 2 were either measured, calculated or estimated. The area of each burn wound
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was determined from images, such as those in Fig 1, using the MetaMorph software, while the
height of the fluid layer was measured to be 1 mm. As described in Experimental set-up, the
initial density of bacteria and the initial concentration of inhibitor are known. The volume of
the exudate is calculated as the product of the wound area and the height of the exudate. We
know that there are about 1.5 × 105 host cells per cm2 and that approximately 17 inhibitors
may bind per host cell [9]. Taking the product of these two values gives us the initial density of
free binding sites, Einit. We define a binding site to consist of the number of host cell binding
receptors occupied by an inhibitor, such that an inhibitor occupies a single site and hence
ϕA = 1 sites inhibitor−1. Inhibitors have been designed to occupy the same number of host cell
binding receptors as a bacterium. Therefore, we also have that ϕBac = 1 sites cell−1. We note
that while an inhibitor occupies the same number of binding sites as a bacterium, a rod-shaped
P. aeruginosa cell (which we have measured to be approximately 1μm×3μm) covers up to three
times the host cell surface area as a spherical (1 μm diameter [23]) inhibitor without occupying
any more sites. Simulations were found to be insensitive to the value of the Hill coefficient, n;
therefore, we set it to unity for simplicity.
We leave our equations in dimensional form so as to make them easier to interpret biologi-
cally and since non-dimensionalisation would not reduce the number of fitted parameters
(although it does reduce the total number of parameters).
Treatment scenarios
In addition to the untreated/control (AFinit ¼ 0) and single inhibitor dose (AFinit > 0) scenarios
based upon Huebinger et al.’s [23] experiments (see Experimental set-up), we consider a fur-
ther six theoretical scenarios, five of which include either regular or continuous debridement
(see Table 3). Since inhibitors operate by blocking bacteria from binding to the wound host
cells, it is intuitive that this may result in the majority of bacteria occupying the free compart-
ment. Thus, any treatment, such as debridement, which removes the exudate, could clear the
free compartment of bacteria—and with them, inhibitors—significantly reducing the total
population size of bacteria when combined with an inhibitor treatment. (Bound bacteria and
inhibitors are left mostly intact by debridement.)
Table 3. Treatment scenarios.
Treatment scenario Description
No treatment No inhibitors or debridement are applied
Single inhibitor dose Inhibitors are applied at time t = 0 hr
Regular inhibitor doses Inhibitors are applied at time t = 0 hr, then again at t = 48 hr and reapplied
every 24 hr
Regular debridement All free bacteria and inhibitors are removed at t = 48 hr and the procedure
repeated every 24 hr
Single inhibitor dose with regular
debridement
Inhibitors are applied at time t = 0 hr, after which all free bacteria and
inhibitors are removed at t = 48 hr and the debridement event repeated every
24 hr
Regular inhibitor doses with regular
debridement
Inhibitors are applied at time t = 0 hr, and free bacteria and inhibitors are
removed at t = 48 hr directly after which inhibitors are reapplied, the
debridement-inhibitor treatment is then repeated every 24 hr
Continuous debridement All free bacteria and inhibitors are removed at t = 48 hr, after which
clearance of bacteria and inhibitors is maintained at a high level
Single inhibitor dose with
continuous debridement
Inhibitors are applied at time t = 0 hr, and all free bacteria and inhibitors are
removed at t = 48 hr, after which clearance of bacteria and inhibitors is
maintained at a high level
https://doi.org/10.1371/journal.pcbi.1006071.t003
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Regular debridement consists of a series of discrete instantaneous debridement events, while
continuous debridement consists of a sustained, high level of clearance (ψBac = ψA = 1000 hr−1)
and may be thought of as the limiting case of regular debridement in which the time between
debridement events tends to zero. While it may not be possible to maintain such a high rate of
clearance in practice, this clearance rate is chosen to determine the theoretical best-case-sce-
nario were such a treatment to be applied. Following a discrete debridement event, it is assumed
that the fluid compartment is restored on the timescale of a few minutes, such that the volume
fluctuation can be neglected.
For each of the treatment strategies, Eqs 1–8 were solved using the Matlab routine ode15s,
a variable-step, variable-order solver based upon numerical differentiation formulas.
The untreated and single inhibitor dose scenarios are those considered in the experiments
and are described above and in Experimental set-up. The key difference between the numerical
simulations (see Numerical solutions) and the experiments is that the simulations extend
beyond the time frame of the experiments.
In the regular inhibitor dose scenario (and the regular inhibitor dose with regular debride-
ment scenario), the repeat doses of inhibitors are identical to the initial dose, AFinit . The second
dose is not applied until 48 hr for consistency with the treatments involving debridement (see
below). As noted in Experimental set-up, a scab forms over the wound after the first 24 hr,
ending clearance and preventing further inhibitor doses from reaching the exudate. Thus, in
practice, inhibitor doses could not be repeated without removing the scab and incurring fur-
ther clearance at levels similar to those in the first 24 hr. However, since we are interested in
the theoretical effect of repeated inhibitor doses independent of clearance, we neglect further
clearance effects in this case. Were we to include additional clearance upon re-treatment with
inhibitor, treatment efficacy would be improved.
In the scenarios involving regular debridement, clearance is re-established for the first 24
hours after each debridement event, with rates given in Table 1 and Table A in S2 Supporting
Information, to account for leakage due to the loss of the scab upon debridement. The first
debridement event is chosen to occur at t = 48 hr, rather than some earlier time, so as to give
the inhibitors time to bind to the host cells.
Sensitivity analyses
We present two sets of sensitivity analyses. The first set (presented in Case A–Case D) shows
the effect of a tenfold increase or decrease in each of the 13 fitted parameters, rF, rB, KF, KB,
αBac, βBac, δB, ηmax, γ, ~cBac, αA, βA and ~cA, on the total number of bacteria either at steady-state
(treatment scenarios 1 and 2) or at t = 90 days = 2160 hr (treatment scenarios 3–8; Figs O–V in
S2 Supporting Information). We truncate the simulations for the latter treatment scenarios at
90 days since simulating treatments with regular inhibitor doses or regular debridement is
computationally expensive and those involving continuous debridement are close to steady-
state by this time. We note that the total population size of bacteria oscillates in those treat-
ments that involve regular debridement, undergoing a sharp drop upon each debridement
event. We plot the value of BT(t) at the peak of the oscillation at t = 90 days (directly prior to
debridement), since we consider that it is by the maximum number of bacteria that the efficacy
of a treatment should be judged.
In the second set of sensitivity analyses (presented in Inhibitor sensitivity analysis), we con-
sider the effect of varying the binding and unbinding rates of inhibitors, αA and βA, in the
space {10−12, 10−11, . . ., 1} × {10−12, 10−11, . . ., 1} upon the total number of bacteria at 4 weeks
(= 672 hr) post infection in the 5 scenarios that involve inhibitor treatment (Figs W, Y, AA,
AC and AE in S2 Supporting Information). We also consider the effect of increasing all
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inhibitor doses by 10 fold from 6.12 × 107 inhibitors cm−3 (the standard value) to 6.12 × 108
inhibitors cm−3 (Figs X, Z, AB, AD and AF in S2 Supporting Information).
Parameter fitting
A combination of Markov Chain Monte Carlo (MCMC) and frequentist methods were used
to fit the model given by Eqs 1–8 to the mean of the experimental data in the untreated and
single inhibitor dose scenarios. Unfortunately, we have insufficient data to generate informa-
tive posterior distributions using the MCMC method; however, we are able to identify a
number of good fits (twelve parameters sets are presented here) and to classify these into
four general cases—A, B, C and D—based upon their qualitative behaviour (see Results). By
considering a range of valid parameter sets, rather than a single good fit, we are able to gain a
more comprehensive understanding of the model behaviour. The fitting procedures used dif-
fer between parameter sets and are summarised in Table A in S1 Supporting Information.
See S1 Supporting Information for more details. We confirmed these fits with a nonlinear
mixed-effects model using the Matlab routine sbiofitmixed, with parameter sets 1–12 as
initial guesses.
Model fits are compared against the experimental data in Fig 4 and Figs A and B in S2
Supporting Information, where parameter sets 2 (Case A), 3 (Case B), 8 (Case C) and 12
(Case D) are presented in Fig 4. Since the experimental data does not distinguish between
free and bound bacteria, we compare it against the simulated total number of bacteria,
BT(t) = VBF(t) + ArBB(t). The model achieves a good fit to the experimental mean in all cases,
remaining mostly within the shaded region denoting the standard error of the mean.
Results
In what follows, we examine the behaviour of Eqs 1–8 in each of the four cases, A–D. For clar-
ity, the results from four representative parameter sets, one from each case, are presented in
the main text: Set 2 from Case A, Set 3 from Case B, Set 8 from Case C and Set 12 from Case D.
For the complete set of results, see S2 Supporting Information. We begin with a steady-state
analysis of the system with and without a single inhibitor dose in order to determine the num-
ber of steady-states and their stability properties. We then consider the behaviour of the time-
dependent problem, simulating the bacterial population dynamics well beyond the time frame
of the experiments. While simulations provide a good fit to the experimental data for all
parameter sets, the model predictions diverge for later times. We investigate why a single
inhibitor dose is or is not effective in each case in the long-term and explore other potential
treatment strategies with the aim of improving efficacy. We consider a treatment to be effective
if it reduces the bacterial burden and to be fully effective if the bacterial burden is eliminated
(such that BT(t)< 1).
Steady-state analysis
Steady-state analyses of Eqs 1–6, in the absence of clearance, with and without a single dose of
inhibitors were performed using Maple. Clearance was neglected since leakage of fluid from
the wound only occurs in the first 24 hours. It was found that the system has two physically
realistic steady-states in both the untreated and single inhibitor dose scenarios for all 12
parameter sets. In each case the first steady-state, at which bacteria are absent, is unstable,
while the second steady-state, at which both free and bound bacteria are present, is stable (see
S3 Supporting Information for more details). By characterising the stability of the system in
this way, we can be sure that we are not overlooking any potential stable steady-state solutions
in the time-dependent simulations below.
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Numerical solutions
Having explored the behaviour of the system at steady-state, we consider the full time-depen-
dent problem (Eqs 1–8). We begin by making a few general comments, before taking Cases
A–D in turn. Further details can be found in S4 Supporting Information.
Fig 4. Comparison of model predictions with experimental data. The discs mark the experimental mean, while the shaded region shows the
standard error of the mean. Simulation results, denoted by the dashed line, show the total number of bacteria, BT(t) (= VBF(t) + ArBB(t)). Note
that the range of the y-axis for the untreated (control) scenario (left-hand column) is twice that for the single inhibitor dose scenario (right-hand
column). There is good agreement between the model and the data in all cases and the overall goodness of fit (mean squared error) is similar for
each parameter set. Eqs 1–8 were solved using ode15s and fitting was performed using a combination of MCMC and frequentist methods (see
Parameter fitting and S1 Supporting Information). See Tables 1 and 2 for parameter values. CFU: colony-forming units.
https://doi.org/10.1371/journal.pcbi.1006071.g004
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In each case we present results to show the evolution in the total number of bacteria,
BT(t) = VBF(t) + ArBB(t) (Fig 5, and Fig D in S2 Supporting Information), the total numbers
of free and bound bacteria, B^FðtÞ ¼ VBFðtÞ and B^BðtÞ ¼ ArBBðtÞ, free and bound inhibitors,
A^FðtÞ ¼ VAFðtÞ and A^BðtÞ ¼ ArABðtÞ, and free binding sites, E^ðtÞ ¼ ArEðtÞ (Fig 6, and Figs E
and F in S2 Supporting Information), and of the individual terms in Eqs 1–4 (Figs G–L in S2
Supporting Information) in the untreated and single inhibitor dose scenarios. We also present
results to show the evolution in the total number of bacteria in the treatment scenarios involv-
ing regular inhibitor doses and regular or continuous debridement (Fig 7, and Figs M and N
in S2 Supporting Information). Lastly, we present a sensitivity analysis showing the effects of a
tenfold increase or decrease in each of the 13 fitted parameters (Figs O–V in S2 Supporting
Information, see Sensitivity analyses for details).
In the remainder of this paper, we distinguish between rate constants, e.g., αBac and δB, and
the rate at which processes occur, e.g., αBacArBFE and δBBB, the former being distinguished
Fig 5. Comparison of bacterial population dynamics in the untreated and single inhibitor dose scenarios. The total number of bacteria, BT(t)
(= VBF(t) + ArBB(t)), is plotted in each case. Simulations extend beyond the time span of the experiments, to 3000 hours = 125 days. Case A: the
bacterial population size is an essentially monotone increasing function of time in both untreated and treated scenarios, reaching an early steady-
state at which the bacterial population size with treatment is roughly half that without; Case B: the bacterial population size with treatment remains
below that without treatment, decreasing gradually after reaching an early maximum; Case C: treatment results in a sustained and significant
increase in the bacterial population size, Case D: treatment causes the bacterial population size to temporarily exceed that without treatment, settling
to a steady-state close to that of the untreated scenario. Eqs 1–8 were solved using ode15s. See Tables 1 and 2 for parameter values.
https://doi.org/10.1371/journal.pcbi.1006071.g005
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from the latter by the use of the word ‘constant’. We also distinguish between the intrinsic
growth rate, e.g., rF, and the rate of logistic growth, e.g., rFBF(1 − BF/KF).
The time-dependent results are summarised in Table 4. Treatments are most effective in
Case A, some of them eliminating the bacterial burden completely. Most treatment scenar-
ios are also effective in Case B. Surprisingly, treatment with inhibitors can actually increase
the bacterial burden in Case C, although some treatments are still effective, while in Case D
Fig 6. Comparison of dependent variables with and without a single dose of inhibitor. The total number of cells (B^ FðtÞ ¼ VBFðtÞ, B^ BðtÞ ¼ ArBBðtÞ),
inhibitors (A^ FðtÞ ¼ VAFðtÞ, A^ BðtÞ ¼ ArABðtÞ) and binding sites (E^ ðtÞ ¼ ArEðtÞ) are plotted in each case. Simulations extend beyond the time span of
the experiments, to 1500 hours = 62.5 days. The insets in the right-hand column show the same plots as in the larger panels, but with the y-axis
spanning [0, 3 × 108]. Cases A and B: the number of bound bacteria are reduced as a result of treatment; Case C: treatment results in an increase in the
number of free bacteria; Case D: treatment increases the time taken to reach a roughly equivalent steady-state to that without treatment. Eqs 1–8 were
solved using ode15s. See Tables 1 and 2 for parameter values.
https://doi.org/10.1371/journal.pcbi.1006071.g006
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Fig 7. Comparison of bacterial population dynamics under a variety of treatment regimes. The total number of bacteria, BT(t) (= VBF(t) +
ArBB(t)), is plotted in each case. Simulations extend beyond the time span of the experiments, to 2000 hours 83 days. The untreated and single
inhibitor dose (‘Inhib.’) scenarios are identical to those in Fig 5. See Treatment scenarios for a description of each treatment strategy. Case A: all
treatments except single and regular inhibitor (‘Reg. Inhib.’) doses eradicate the bacterial population (such that BT(t)< 1); Case B: regular inhibitor
doses with regular debridement (‘Reg. Inhib. and Reg. Deb.’) and a single inhibitor dose with continuous debridement (‘Inhib. and Cont. Deb.’) are
most effective, reducing the bacterial population size by an order of magnitude or more; Case C: only treatments involving continuous debridement
(‘Cont. Deb.’ and ‘Inhib. and Cont. Deb.’) are effective, reducing the bacterial population size by an order of magnitude or more; Case D: no
treatment strategy is effective. Eqs 1–8 were solved using ode15s. See Tables 1 and 2 for parameter values.
https://doi.org/10.1371/journal.pcbi.1006071.g007
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all treatments are ineffective, the bacterial burden settling to its untreated steady-state in all
scenarios.
When effective, treatment with inhibitors may reduce the total bacterial burden in two
ways. Firstly, inhibitors may reduce the number of bound bacteria through competition for
binding sites. The second way, which may follow as a consequence of the first, is by reducing
the rate of production of daughter cells by bound bacteria.
We note that the maximum proportion of bound daughter cells to enter the bound com-
partment, ηmax, ranges between O(10−10) and O(10−2), across the 12 parameter sets considered
(see Table 1, and Table A in S2 Supporting Information). Therefore, the majority of bound
daughter cells enter the exudate in all cases (though, once there, they will not continue to
divide if the free carrying capacity is exceeded). This insight is not intuitively obvious, demon-
strating the benefit of mathematical modelling.
Case A. Case A includes parameter sets 1 and 2 (see S2 Supporting Information), where
the results from Set 2 are presented in the main text.
In Case A, inhibitors are predicted to bind rapidly to the surface, achieving quasi-steady-state
in 15–30 mins in the single dose scenario (see Fig 6, and Fig F in S2 Supporting Information).
This reduces the number of bound bacteria, compared with the untreated scenario, and, as a
consequence, reduces the contribution of daughter cells to the exudate from the bound com-
partment (compare Figs G and I in S2 Supporting Information). In Set 2, the treatment-induced
reduction in BT(t) is due largely to the drop in the number of bound bacteria as a result of
replacement by inhibitors (the drop in BF(t) being small), while in Set 1 the latter effect is the
more significant, the reduced flux of bound daughter cells into the free compartment resulting
in a significant reduction in the number of free bacteria.
Surprisingly, the total number of free bacteria, B^FðtÞ, is predicted to exceed its carrying
capacity, VKF, at steady-state, in the untreated scenario, in both Sets 1 and 2 (and thus the logis-
tic growth term becomes a death term). This is valid since, as noted in Model formulation, the
carrying capacities in this model represent the maximum number of bacteria that can be sup-
ported with nutrients in each compartment, rather than the maximum number that can fit into
each compartment. Examination of the sizes of the terms in Eq 1 (see Fig G in S2 Supporting
Information) reveals that this is due to the contribution of daughter cells from the bound com-
partment, the bacterial binding and unbinding rates essentially balancing each other.
Table 4. Summary of results.
Treatment scenario Case A Case B Case C Case D
Single inhibitor dose (✔) (✔) ✘ —
Regular inhibitor doses (✔) (✔) ✘/—/(✔) —
Regular debridement ✔ —/(✔) —/(✔) —
Single inhibitor dose with regular debridement ✔ ✘/—/(✔) —/(✔) —
Regular inhibitor doses with regular debridement ✔ (✔)/✔ ✘/—/✔ —
Continuous debridement ✔ (✔)/✔ —/(✔)/✔ —
Single inhibitor dose with continuous debridement ✔ (✔)/✔ —/✔ —
‘✔’ (dark green): treatment is highly effective, reducing the bacterial burden by at least two orders of magnitude and
in some cases eliminating it completely; ‘(✔)’ (light green): treatment is effective, reducing the bacterial burden by no
more than two orders of magnitude; ‘—’ (yellow): treatment has little effect; ‘✘’ (red) treatment increases the
bacterial burden. Multiple symbols are used in those cases and treatment scenarios where there is variation between
parameter sets; in this situation the cell colour corresponds to the least effective treatment. (Colour online.)
https://doi.org/10.1371/journal.pcbi.1006071.t004
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Regular inhibitor dosing results in a total bacterial population size almost identical to that
in the single inhibitor dose case. Each of the other treatment regimes examined are predicted
to be successful in eliminating the bacterial population (such that BT(t)< 1) given sufficient
time—regular debridement takes the longest at 200 hr (Set 1) or 1700 hr (Set 2), while continu-
ous debridement takes 70 hr (Set 1) or 140 hr (Set 2) and treatments combining inhibitor with
regular or continuous debridement are much more rapid, elimination of bacteria occurring
upon the initial debridement event at 48 hr (see Fig 7, and Figs M and N in S2 Supporting
Information). Regular and continuous debridement are effective in eliminating bacteria in
both Sets 1 and 2, even when inhibitors are not used, since the rate constant of bacterial
unbinding is high (see Table 1, and Table A in S2 Supporting Information).
Case B. Case B includes parameter sets 3–7 (see S2 Supporting Information), where the
results from Set 3 are presented in the main text.
The inhibitor binding rate constants in Case B are 4–5 orders of magnitude lower than those
in Case A (see Table 1, and Table A in S2 Supporting Information) and consequently inhibitors
take longer to reach quasi-steady-state—on the order of 100–200 hr compared with 15–30 mins
for Case A. Having reached quasi-steady-state, inhibitors continue to bind at a lower rate than
during the initial rapid phase (see Fig 6, and Fig F in S2 Supporting Information, and see Cases
C and D below for comparison).
Treatment with inhibitors results in a significant reduction in the steady-state population
size of bound bacteria (see Fig 6, and Fig F in S2 Supporting Information). However, surpris-
ingly, it may either increase (Sets 3, 4 and 6) or decrease (Sets 5 and 7) the number of free bac-
teria, depending upon the effect of treatment upon the logistic growth of bound bacteria. Due
to the quadratic dependence of the logistic growth rate of bound bacteria upon their density, a
drop in the density of bound bacteria may either increase of decrease the rate of logistic growth
and hence the flux of bound daughter cells into the free compartment. This is determined by
the densities between which the bound compartment shifts and the bound carrying capacity
(see Fig 8). Despite this, a single inhibitor dose is effective in reducing the total bacterial popu-
lation size in all parameter sets, since the loss in bound bacteria is greater than the gain in free
bacteria.
Regular debridement alone is predicted to be ineffective since there are a significant num-
ber of bound bacteria at the untreated steady-state and the rate constants of bacterial unbind-
ing are much lower than in Case A (see Table 1, and Table A in S2 Supporting Information);
however, continuous debridement is effective since free bacteria are eliminated while bound
bacteria unbind gradually from the surface and are cleared (see Fig 7, and Figs M and N in S2
Supporting Information). Combining continuous debridement with inhibitors improves effi-
cacy, compared with continuous debridement alone, as would be expected (see Fig N in S2
Supporting Information). Of those treatments which involve regular debridement, that which
includes regular inhibitor doses is most effective, the inhibitors serving to displace the bound
bacteria and debridement to remove free bacteria.
Case C. Case C includes parameter sets 8–11 (see S2 Supporting Information), where the
results from Set 8 are presented in the main text.
In the untreated scenario, BT(t) evolves in a qualitatively similar way to Cases B and D;
however, we have the surprising result that application of a single inhibitor dose leads to an
increase in BT(t) at steady-state.
This last result may be explained as follows. The number of bound bacteria exceeds that of
free bacteria in the untreated scenario for all parameter sets in Case C (see Fig 6, and Fig E in
S2 Supporting Information). Application of a single inhibitor dose results in a slight reduction
in the number of bound bacteria in Sets 8, 9 and 11 and a slight increase in Set 10, while the
number of free bacteria increases by an order of magnitude or more in all sets (Fig F in
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S2 Supporting Information). Inhibitors bind more rapidly to the host cells than bacteria, with
AB(t) achieving its maximum value between 40–120 hr. However, whereas AB(t) is a monotone
increasing function in Cases A and B, in Case C it slowly decreases, subsequent to the initial,
more rapid, binding phase. Inhibitors outcompete bacteria for binding sites initially because
they greatly outnumber them; however, as the number of free bacteria increases, bacteria
begin to replace inhibitors. This is because, while the binding rate constants of bacteria
and inhibitors are of the same order of magnitude, inhibitors have much higher unbinding
rate constants, such that their association constant is much smaller (see Table 1, and
Table A in S2 Supporting Information). The difference between association constants is less
significant in Set 11, hence the effect is less pronounced in this case (see Fig F in S2 Supporting
Information).
Bacteria are predicted to populate the bound compartment mainly through binding (as
opposed to logistic growth) in both the untreated and single inhibitor dose scenarios, but the
binding rate is lower in the treated scenario, since inhibitors reduce the number of free binding
sites (see Figs H and J in S2 Supporting Information). Consequently, it takes bound bacteria
longer to reach their steady-state value, during which time the logistic growth of bound bacte-
ria is maintained at a higher level (the population size being kept well below carrying capacity
at which logistic growth would go to zero), the majority of daughter cells entering the free
compartment, pushing the population size of free bacteria well above untreated levels. As
bound bacteria approach their carrying capacity their logistic growth rate diminishes, reducing
the supply of bacteria to the free compartment and the system settles to steady-state.
Regular debridement and/or inhibitor doses are ineffective in significantly reducing the
bacterial population size, except in Set 11, where regular inhibitor doses with regular
Fig 8. The effect of a drop in bound bacterial density upon their logistic growth rate. Treatment with inhibitor
usually results in a drop in the density of bound bacteria, BB(t). The effect of this reduction in BB(t) upon the logistic
growth rate, dBB/dt = rBBB(1 − BB/KB), depends upon the untreated value of BB(t), the value to which it is reduced and
the carrying capacity, KB. In this example, a reduction in BB(t) from A to B results in an increase in the logistic growth
rate, while a reduction from B to C results in a decrease in the logistic growth rate. Parameter choices are for
demonstration purposes only.
https://doi.org/10.1371/journal.pcbi.1006071.g008
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debridement reduced the population size by three orders of magnitude (Fig 7, and Fig M in S2
Supporting Information). Continuous debridement with and without inhibitor is effective in
all cases except Set 10 where BT(t) tends to untreated levels at steady-state (Fig 7, and Fig N in
S2 Supporting Information). Treatments involving continuous debridement reduce BT(t) by
an order of magnitude in Sets 8 and 9 and to O(100) or below in Set 11. No treatment is suc-
cessful in completely eliminating the bacteria burden.
Case D. Case D consists of parameter set 12, which is presented in the main text.
Application of a single inhibitor dose slows the dynamics of the system, but results in essen-
tially the same numbers of free and bound bacteria at steady-state (see Fig 6, and Figs E and F
in S2 Supporting Information). Inhibitors bind rapidly initially, reaching quasi-steady-state in
a couple of hours. This is followed by a more gradual period of unbinding as bacteria outcom-
pete inhibitors for binding sites (see Fig 6, and Fig F in S2 Supporting Information). Inhibitors
slow the dynamics by reducing the rate at which bacteria bind to the surface and by reducing
the proportion of bound daughter cells which can remain bound to the surface.
Sensitivity analysis suggests that all treatments would be improved if KB could be reduced
in some way (see Fig O–V in S2 Supporting Information).
Inhibitor sensitivity analysis. We have seen above that treatment is always effective in
Case A, is sometimes effective in Cases B and C and is never effective in Case D. The question
then arises: can we modify the treatment strategies in such a way as to make at least some of
them effective in all cases? In this section we explore two ways in which this might be achieved.
Firstly, we investigate how treatment efficacy varies with changes in the binding and unbind-
ing rate constants of inhibitors (αA and βA); and, secondly, we examine the effect of increasing
the number of inhibitors used in each inhibitor dose (see Sensitivity analyses for details). Since
we are varying parameters which relate only to the inhibitors, we consider only those five treat-
ment scenarios that involve dosing with inhibitor.
The panels in Fig 9 and Figs W–AF in S2 Supporting Information show log10(BT(672)) at
each point in (log10(αA), log10(βA)) parameter space (where 672 hr = 4 weeks). Red curves
mark the contours along which BT(672) = 1 and thus demarcate the boundary between the
region of parameter space to the left of the curve, where BT(672)> 1 and treatment has failed
to eradicate the bacterial population, and the region to the right of the curve, where BT(672)<
1 and treatment has successfully eliminated the bacterial population. In this section, we con-
sider treatment to be effective only if it eliminates the bacterial burden, such that BT(672) < 1.
Examination of Figs W–Z in S2 Supporting Information reveals that neither single nor
regular inhibitor doses are predicted to be capable of eliminating the bacterial population for
any of the 12 parameter sets considered. In contrast, the remaining three treatments (a single
inhibitor dose with regular debridement, regular inhibitor doses with regular debridement
and a single inhibitor dose with continuous debridement) are all predicted to be capable of
eradicating the bacterial population, provided that the inhibitor binding rate constant is high
enough and the unbinding rate constant is low enough. Therefore, in what follows, we focus
upon these three treatment scenarios (Fig 9, and Figs AA–AF in S2 Supporting Information).
Treatment is predicted to be successful throughout the region of parameter space considered
for all three treatment scenarios in Set 1 and for the single inhibitor dose with continuous
debridement scenario in Set 2 (see Fig 9, and Figs AA–AF in S2 Supporting Information).
Indeed, continuous debridement alone is successful in both Sets 1 and 2 as is regular debride-
ment alone in Set 1 (see Fig 7, and Figs M and N in S2 Supporting Information). Each treatment
strategy is more effective, that is bacteria are eliminated in a larger region of (αA,βA) parameter
space, when more inhibitors are used per dose. On average, across the 12 parameter sets, a single
inhibitor dose with continuous debridement is predicted to be the most effective strategy, fol-
lowed by regular inhibitor doses with regular debridement and then single inhibitor dose with
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regular debridement (see Fig 9, and Figs AA–AF in S2 Supporting Information). Treatment effi-
cacy shows a greater sensitivity to αA than to βA in the ranges considered for these parameters,
such that even for values as large as βA = 1 hr
−1, a value of αA can be found such that treatment
eliminates the bacterial population for all treatment strategies, doses and parameter sets.
Fig 10 shows the evolution in the total number of bacteria, BT(t), for the full range of treat-
ment strategies in Cases A–D, where αA = 10
−2 hr−1 sites−1 and βA = 10
−2 hr−1. These values
Fig 9. Sensitivity analysis to determine the effect of varying inhibitor adhesion kinetics upon treatment efficacy. For each panel, αA and βA = 10
−12,
10−11, . . ., 10−1 and 1, where a log10 scale is used on both axes. The value of log10(BT(672)) is plotted at each point in parameter space, where BT(672)
(= VBF(672) + ArBB(672)) is the total number of bacteria after 4 weeks (672 hr). The colour scheme is calibrated to maximise clarity, such that values of
log10(BT(672)) −1 appear in black. The red curve (colour online) traces the contour along which BT(672) = 1, such that BT(672)> 1 to the left and
BT(672)< 1 to the right of this curve. Treatment efficacy improves with increasing αA and decreasing βA. On average, treatment with a single inhibitor
dose with continuous debridement is the most effective treatment, followed by regular inhibitor doses with regular debridement; a single inhibitor dose
with regular debridement being the least effective of the three. Eqs 1–8 were solved using ode15s.AFinit ¼ 6:12 10
7 inhibitors cm−3 (the standard
value). See Tables 1 and 2 for the remaining parameter values.
https://doi.org/10.1371/journal.pcbi.1006071.g009
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Fig 10. Comparison of bacterial population dynamics under a variety of treatment regimes with modified inhibitors. The total number of
bacteria, BT(t) (= VBF(t) + ArBB(t)), is plotted in each case. Simulations extend beyond the time span of the experiments, to 672 hours = 28 days.
Bacteria are eliminated (BT(t)< 1) by t = 672 hr for all treatment strategies combining inhibitor with regular or continuous debridement in all
cases. In Case D, BT(672)> 1; however, it descends below 1 at an earlier time point so bacteria may be considered to have been eliminated by
t = 672 hr. Eqs 1–8 were solved using ode15s. Parameter values: αA = 10−2 hr−1 sites−1 and βA = 10−2 hr−1. See Tables 1 and 2 for the remaining
parameter values.
https://doi.org/10.1371/journal.pcbi.1006071.g010
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are chosen, based upon the sensitivity analysis above, such that all those treatment strategies
which combine inhibitor with regular or continuous debridement are effective in eliminating
the bacterial population, that is BT(672) < 1. The only exception is for the single inhibitor dose
with continuous debridement treatment in Case D, where BT(672) 1.07; however, BT(t)< 1
for t 2 (48, 665), so treatment can be considered to have eliminated the bacterial population in
this case also. Therefore, our models make the encouraging prediction that, in theory, treat-
ment could be rendered successful in all cases.
Discussion
As bacteria gain increasing resistance to antibiotics it is vital that we develop alternative treat-
ment strategies. Anti-virulence treatments—specifically MAM7-coupled beads, which operate
by competitively inhibiting the binding of bacteria to host cells—present a promising comple-
ment or alternative to antibiotics. Opinion as to the likely efficacy of such treatments is mixed,
with some suggesting that their utility may be limited to preventing the initiation of a bacterial
infection (prophylaxis) as opposed to treating a pre-existing infection (therapy) [6, 10, 47, 48].
In this paper we have used mathematical models to help us interpret the results of an experi-
mental model, involving the inhibitor treatment of a burn wound infected by P. aeruginosa in
the rat (see Experimental set-up). Our models allow us to predict the conditions under which
treatment with inhibitors will be effective and to explore ways in which inhibitor dosing could
be augmented to improve efficacy.
Mathematical models were fitted to experimental data using a combination of MCMC and
frequentist techniques (Parameter fitting). A number of close fits were obtained (12 parameter
sets are explored here) and classified into four qualitatively different cases (A–D).
Given the significant qualitative, and not merely quantitative, differences in predicted treat-
ment outcomes between Cases A–D, this work highlights the importance of considering a
range of viable parameter sets. Had a single parameter set been chosen, our conclusions would
have differed markedly from those in this more comprehensive study. It may be that different
parameters sets could reflect inter-patient variability, as well as different bacterial species.
Indeed, a variety of Gram negative and Gram positive bacteria have been found to infect burn
wounds (see, for example, [15–17, 19]).
Eight treatment scenarios were considered for each of Cases A–D (see Treatment scenarios
for details). The untreated and single inhibitor dose scenarios were considered in the experi-
mental model, while the rest are theoretical treatments that remain to be tested experimentally.
Continuous debridement, with clearance rates on the order of magnitude of those used in
simulations, is probably not practically achievable; though it might be possible to maintain a
high level of clearance using negative pressure wound therapy (see Introduction). In any case,
these simulations allow us to determine the theoretical best-case scenario where debridement
is applied.
Simulations for the 8 treatment scenarios in Cases A–D reveal a range of outcomes and pro-
vide insight into the bacterial population dynamics (Case A–Case D). Before considering each
case in turn, a few general observations can be made. Firstly, while the ratio between the number
of bacteria at carrying capacity in the free and bound compartments, VKF and ArKB respectively,
varies between parameter sets, the intrinsic growth rate in the bound compartment, rB, is consis-
tently greater than that of the free compartment, rF (see Table 1 and Table A in S2 Supporting
Information). This suggests that the bound compartment is more favourable to the growth of
bacteria than the free compartment, agreeing nicely with Huebinger et al.’s [23] speculative
explanation for the efficacy of inhibitor treatment. This might be because bound bacteria have
access to additional nutrients derived from the host cells, not available to free bacteria.
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Our model predicts that in order for inhibitor treatment to be effective, inhibitors must
bind rapidly and numerously. If they do not, then treatment may actually worsen a bacterial
infection. If inhibitors bind in sufficient quantities to the host cells, then the number of bacte-
ria in the bound compartment and hence their rate of logistic growth will remain small, reduc-
ing the flux of bound daughter cells into the free compartment. However, if inhibitors bind in
lower numbers, then while the number of bound bacteria at steady-state may be reduced, their
logistic growth rate increases (see Fig 8) as does the flux of bound daughter cells into the free
compartment, with the result that inhibitor treatment increases the total number of bacteria at
steady-state above its untreated value.
If debridement is applied too early, as in Set 7, it may reduce treatment efficacy as inhibitors
will have had insufficient time to bind before those in the free compartment are removed. If
inhibitor binding rates could be determined experimentally then this would allow us to deter-
mine the optimum timing of debridement in relation to inhibitor dosing.
All treatments are effective in significantly reducing the bacterial population size in Case A.
In Case B, all treatments except regular debridement and a single inhibitor dose with regular
debridement are consistently effective. Counterintuitively, a single inhibitor dose increases the
bacterial burden in Case C, with treatments involving continuous debridement being the most
effective. Lastly, in Case D, all of the treatment strategies result in a steady-state bacterial popu-
lation size similar to that without treatment.
The differences in behaviour between Cases A–D may be explained, to some extent, by the
differences in the bacteria and inhibitor association constants and the ratio of these constants
(see Table 1, and Table A in S2 Supporting Information). The bacteria association constant is
lower in Case A than in Cases B–D, while the inhibitor association constant and the ratio of
these constants are lowest in Case A, highest in Cases C–D and take intermediate values in
Case B. Treatments are more effective where the inhibitor association constant is higher and
the bacterial association constant is lower, and hence where the ratio of association constants
is lower. The qualitative difference between Cases C and D is less significant than between the
other cases, thus it is not surprising that the order of magnitude of their association constants
and their ratio are not distinct.
Given the correlation between bacteria and inhibitor association constants and treatment
efficacy, a natural way to seek to improve treatment would be to decrease the bacterial associa-
tion constant or to increase the inhibitor association constant, shifting the system behaviour
towards that in Case A. The bacterial association constant could be reduced by treating with a
molecule that binds to and blocks bacterial adhesins used for binding to the host cells e.g. man-
nosides, which bind FimH [12]. In order for these molecules not to interfere with the inhibitor
treatment they would need to either bind to an adhesin other than MAM7 or be applied to a
wound before the inhibitor dose, giving the molecules time to bind to the bacteria. The inhibi-
tor association constant could be increased by coupling more MAM7 molecules to each bead.
Sensitivity analysis of the inhibitor binding rate constant, unbinding rate constant and dose
concentration predicts conditions under which treatments involving inhibitor would eliminate
the bacterial burden within 28 days (Inhibitor sensitivity analysis, Fig 9, and Figs W–AF in S2
Supporting Information). Neither a single nor regular doses of inhibitor on their own were
predicted to be capable of eliminating the bacterial population, though they may reduce it by
several orders of magnitude. This is to be expected since, on its own, inhibitor can only prevent
bacteria from entering the bound compartment, and is unable to remove bacteria from the
free compartment. Encouragingly, when combined with regular or continuous debridement,
inhibitor treatment is predicted to have the potential to eliminate the bacterial population. A
single inhibitor dose with continuous debridement is predicted to be the most effective treat-
ment, followed by regular inhibitor doses with regular debridement, with a single inhibitor
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dose with regular debridement being the least effective of the three. Treatment is predicted to
be more effective for higher binding rate constants, lower unbinding rate constants and higher
concentration inhibitor doses, where treatment efficacy is more sensitive to the binding rate
constant than to the unbinding rate constant.
In future work we will proceed on two fronts: experimental and theoretical. We will con-
duct further experiments to test our model predictions and to improve model parametrisation.
Experiments like those described in Experimental set-up could be performed over a longer
time-span and separate measurements made for the numbers of free and bound bacteria and
inhibitors. This would enable us to refine the range of possible parameter sets. This would also
be aided by more regular wound imaging than the current daily set-up. Further experiments
to test the model predictions concerning the other treatment strategies suggested here would
also be valuable. We will develop our mathematical modelling in at least two directions. Firstly,
we will incorporate treatment with antibiotics, seeking to determine the optimum treatment
regime when combined with inhibitor dosing and regular or continuous debridement. Sec-
ondly, we will consider a discrete-stochastic cellular automata model to capture some of the
mechanisms in the system in more detail, including the spatial spread of infection, which has
been shown experimentally to be limited upon treatment with inhibitor [23]. Our models
could also be extended to incorporate quorum sensing and biofilm formation.
In conclusion, our mathematical models suggest that inhibitor treatment could be effective
in eliminating or significantly reducing the bacterial burden in a burn wound when combined
with regular or continuous debridement. Where inhibitor treatment is effective, it operates
both by preventing bacteria from occupying the host cells (where growth rates are predicted to
be higher) and, consequently, by reducing the flux of bound daughter cells into the exudate.
Our model predicts that inhibitor treatments, in particular those involving regular or continu-
ous debridement, could be effective when used both prophylactically and therapeutically. Our
models further predict that treatment efficacy can be improved by optimising inhibitor design
and dosing schedules.
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